SCIENTEX is a Healthcare Contract Business Development Organization


Created in 2006, SCIENTEX Group is a renowned healthcare focused CBDO presenting 14 international business awards with a global footprint thanks to 120 achieved deals in track record through 38 mandates from our US, UK & EU clients.


Join my +75K linkedin contacts, connections & followers :


Part-time & shared CBO & CFO : SCIENTEX is acting as a transition management company for healthcare startups, covering financing & business development operations, on sell & buy side: from seed capital to public offerings & follow-on financings, M&A, business development & licensing, R&D partnering and commercial agency.

 SCIENTEX has developed 4 products & services in order to boost all corporate activities, by leveraging the track record of its two founders (120 deals since 1999 including private and public equity financing, R&D partnering, BusDev & licensing, IPOs, M&A, Marketing & Sales on both sell & buy sides & 38 missions since 2006 & +26 board member positions since 1999) :  

  • SCIENTEX = Hands-on & executive support covering CFO & CBO functions for biotech/pharma/medtech/CRO, holding of billing, thus avoiding high costs & taxes, heaviness, sick leaves, holidays and legal constraints of the french pharma legal labor agreement.
  • BIOTECHNEWS = corporate & PR news push services covering the healthcare market thanks to a large contact database updated monthly including +81 000 industrial healthcare dealmakers, +3500 tech journalists, +10 000 inside financing & 45 000 life sciences academics.
  • BIOFOCUS = a >20 Go data analysis & market intelligence database focused on healthcare market; sourced, built and updated monthly from main market intelligence providers & investment banks.
  • BIOPHARMACAPITAL = Financing operations from seed capital to public offerings, follow-on & Investor Relations supportsbased on our contact database : +6000 contacts inside public & private equity, french speaking family office & business angels, +3500 wealth managers and our track-record as venture capitalist during 10 years and our last IPO & follow-on financings (2014-18) with CROSSJECT.

Thanks to a highly pragmatic approach fully dedicated to milestones achievments, SCIENTEX's associates are structured to work 60% more (2430 hours/year) than the 1529 hours, average working time in Europe. Thanks to its low cost fees and its support eligible for export subsidies, SCIENTEX will allow its clients to reduce their labor costs compared to FTE. The 2 associates of SCIENTEX are limiting their supports to 3 clients max in parallel in order to guarantee their full intensive, full time , and fully dedicated supports. Generally speaking, for transition management missions, SCIENTEX's associates are supporting operationally CFO+CBO functions on a day to day basis , working remotely and commuting internationally , without any outsourcing.


Document Adobe Acrobat [1.9 MB]
Version imprimable | Plan du site
SCIENTEX SAS and its subsidiary OCEAN5 - Villa GOADIK , 49 avenue du Littoral 44380 PORNICHET - FRANCE - - - - french mobile : +33 645 523 540 -